EXACT Therapeutics announces first half 2023 interim results

28 Sep 2023 08:00 CEST

28 September, 2023: EXACT Therapeutics AS (“EXACT-Tx”, Euronext Growth: EXTX), a
clinical stage precision health company utilising Acoustic Cluster Therapy
(ACT®) across multiple therapeutic areas, today announces its interim results
for the first half 2023.

The interim report and presentation for the first half year 2023 are also
available on the company's website: www.exact-tx.com.

A presentation of the first half year 2023 followed by a Q&A session will be
held today at 14:00-15:00 CET at Carnegie's offices at Aker Brygge, Fjordalleen
16, and through a live webcast.

CEO, Per Walday, CFO, John M. Edminson and CMO, Amir Snapir will hold the
presentation. Participants who want to participate in the live webcast or by
physical attendance are asked to send an email to anne.myren@carnegie.no.

For more information, please contact:
Per Walday
CEO EXACT Therapeutics
Email: per.walday@exact-tx.com

About EXACT-Tx:
EXACT-Tx is a clinical-stage Norwegian precision health company developing a
technology platform for targeted therapeutic enhancement – Acoustic Cluster
Therapy (ACT®). ACT follows a unique approach to ultrasound-mediated, targeted
drug enhancement – with the potential to significantly amplify the clinical
utility of a wide range of therapeutic agents across a multitude of indications
including within oncology (chemotherapy, immunotherapy) and brain diseases.
www.exact-tx.com

About ACT®:
• ACT is a proprietary formulation consisting of microbubbles and microdroplets
that are activated through the application of ultrasound with the consequent
increase in targeted delivery of a co-administered therapeutic agent.
• ACT is supported by a strong and broad preclinical package demonstrating
therapeutic enhancement in multiple oncology models (pancreatic, breast, colon,
prostate) as well as blood-brain barrier penetration.
• Initial focus of the Company is oncology, however the ACT platform has
potential across therapeutic areas (CNS, immunotherapy) and product classes.

Forward looking statements: This announcement and any materials distributed in
connection with this announcement may contain certain forward-looking
statements. By their nature, forward-looking statements involve risk and
uncertainty because they reflect the Company's current expectations and
assumptions as to future events and circumstances that may not prove accurate. A
number of material factors could cause actual results and developments to differ
materially from those expressed or implied by this forward-looking statement.

This information is subject to the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.

More information:
Access the news on Oslo Bors NewsWeb site

600437_EXACT H1 2023 presentation.pdf
600437_EXACT H1 2023 interim rapport.pdf